ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Differential and state-dependent effects of the GluN2A-selective positive allosteric modulator GNE-5729 on executive functions.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cognitive deficits in executive functions such as working memory and cognitive flexibility are central to many brain disorders, yet effective treatments remain limited. Dysfunction of GluN2A-containing NMDA receptors (NMDAR) contributes to these impairments, and positive allosteric modulators (PAM) that selectively enhance GluN2A function offer a promising strategy to rescue cognitive deficits while preserving physiological neurotransmission. However, it remains unclear whether PAM-driven GluN2A potentiation can rescue mechanistically distinct, pharmacologically induced impairments and whether the efficacy of GluN2A-PAMs differs across executive domains and sexes. Here, we assessed the effects of GNE-5729, a brain-penetrant GluN2A-selective PAM, on executive functions in mice. GNE-5729 showed no overall effect on working memory performance in the Y-maze, but improved performance in mice with low baseline spontaneous alternations, indicating a baseline-dependent effect. It also rescued working memory deficits induced by dl-amphetamine and scopolamine, which disrupt neuromodulatory regulation while leaving NMDAR channels functionally accessible. In contrast, GNE-5729 failed to reverse MK-801-induced impairments, consistent with MK-801's non-competitive pore blockade of NMDAR. Notably, GNE‑5729 effects showed sex‑dependent patterns, with female mice displaying more pronounced effects. GNE-5729 had no effects on cognitive flexibility in the attentional set-shifting task (ASST) and did not alter prefrontal GluN2A expression, though it disrupted the association between endogenous GluN2A levels and ASST performance observed in controls. Together, these findings indicate that GNE-5729 exerts effects under conditions of reduced baseline performance or disrupted neuromodulatory signaling and demonstrates differential effects across executive domains, supporting a state-dependent therapeutic profile of GluN2A-targeted modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.